NANOGNB
gene geneOn this page
Summary
NANOGNB (NANOG neighbor homeobox, HGNC:24958) is a protein-coding gene on chromosome 12p13.31, encoding NANOG neighbor homeobox (Q7Z5D8).
Predicted to enable DNA-binding transcription factor activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in nucleus.
Source: NCBI Gene 360030 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 30 total
- MANE Select transcript:
NM_001145465
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:24958 |
| Approved symbol | NANOGNB |
| Name | NANOG neighbor homeobox |
| Location | 12p13.31 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000205857 |
| Ensembl biotype | protein_coding |
| OMIM | 620692 |
| Entrez | 360030 |
Gene structure
Transcript identifiers
Ensembl transcripts: 2 — 2 protein_coding
ENST00000382119, ENST00000640040
RefSeq mRNA: 1 — MANE Select: NM_001145465
NM_001145465
CCDS: CCDS44826
Canonical transcript exons
ENST00000382119 — 4 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001490971 | 7773800 | 7774121 |
| ENSE00001490972 | 7770439 | 7770518 |
| ENSE00001490973 | 7769983 | 7770315 |
| ENSE00001490974 | 7765216 | 7765387 |
Expression profiles
Bgee: expression breadth tissue_specific, 8 present calls, max score 79.43.
Top tissues by expression
112 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 79.43 | gold quality |
| colonic epithelium | UBERON:0000397 | 42.86 | silver quality |
| bone marrow cell | CL:0002092 | 41.94 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 41.56 | silver quality |
| stromal cell of endometrium | CL:0002255 | 39.30 | gold quality |
| granulocyte | CL:0000094 | 38.75 | gold quality |
| ganglionic eminence | UBERON:0004023 | 37.62 | silver quality |
| ventricular zone | UBERON:0003053 | 36.48 | gold quality |
| cortical plate | UBERON:0005343 | 36.47 | gold quality |
| liver | UBERON:0002107 | 32.30 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 32.15 | gold quality |
| primary visual cortex | UBERON:0002436 | 31.26 | gold quality |
| leukocyte | CL:0000738 | 31.11 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 31.10 | silver quality |
| sural nerve | UBERON:0015488 | 30.93 | gold quality |
| monocyte | CL:0000576 | 30.76 | gold quality |
| urinary bladder | UBERON:0001255 | 30.56 | gold quality |
| lymph node | UBERON:0000029 | 30.42 | silver quality |
| vermiform appendix | UBERON:0001154 | 30.05 | silver quality |
| blood | UBERON:0000178 | 29.74 | gold quality |
| right uterine tube | UBERON:0001302 | 29.64 | gold quality |
| right lobe of liver | UBERON:0001114 | 29.09 | gold quality |
| tonsil | UBERON:0002372 | 28.49 | gold quality |
| duodenum | UBERON:0002114 | 28.14 | gold quality |
| cortex of kidney | UBERON:0001225 | 28.11 | gold quality |
| placenta | UBERON:0001987 | 27.90 | silver quality |
| islet of Langerhans | UBERON:0000006 | 27.45 | silver quality |
| metanephros cortex | UBERON:0010533 | 26.17 | gold quality |
| kidney | UBERON:0002113 | 26.09 | gold quality |
| muscle of leg | UBERON:0001383 | 26.04 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-36552 | yes | 166.38 |
| E-ANND-3 | yes | 3.61 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
19 targeting NANOGNB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-548AJ-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-548X-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-6755-5P | 99.95 | 65.59 | 464 |
| HSA-MIR-548J-3P | 99.94 | 72.61 | 4881 |
| HSA-MIR-548AE-3P | 99.93 | 72.66 | 4867 |
| HSA-MIR-548AH-3P | 99.93 | 72.54 | 4872 |
| HSA-MIR-548AM-3P | 99.93 | 72.54 | 4872 |
| HSA-MIR-548AQ-3P | 99.93 | 72.66 | 4867 |
| HSA-MIR-5582-3P | 99.86 | 72.48 | 4221 |
| HSA-MIR-139-5P | 99.80 | 69.50 | 1399 |
| HSA-MIR-136-5P | 99.50 | 67.26 | 1153 |
| HSA-MIR-578 | 99.46 | 68.36 | 1787 |
| HSA-MIR-569 | 99.42 | 66.32 | 1009 |
| HSA-MIR-4443 | 98.02 | 66.25 | 1928 |
| HSA-MIR-7855-5P | 97.39 | 67.18 | 925 |
| HSA-MIR-3121-5P | 97.30 | 66.62 | 1146 |
| HSA-MIR-6841-5P | 97.19 | 67.29 | 409 |
| HSA-MIR-5195-5P | 90.84 | 65.09 | 287 |
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | rims2b | ENSDARG00000102690 |
| drosophila_melanogaster | Rim | FBGN0053547 |
| caenorhabditis_elegans | WBGENE00006750 |
Paralogs (4): RIMS1 (ENSG00000079841), RIMS4 (ENSG00000101098), RIMS3 (ENSG00000117016), RIMS2 (ENSG00000176406)
Protein
Protein identifiers
NANOG neighbor homeobox — Q7Z5D8 (reviewed: Q7Z5D8)
Alternative names: Homeobox protein C14
All UniProt accessions (2): A0A1W2PR93, Q7Z5D8
UniProt curated annotations — full annotation on UniProt →
Subcellular location. Nucleus.
RefSeq proteins (1): NP_001138937* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001356 | HD | Domain |
| IPR009057 | Homeodomain-like_sf | Homologous_superfamily |
Pfam: PF00046
UniProt features (4 total): chain 1, DNA-binding region 1, region of interest 1, compositionally biased region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q7Z5D8-F1 | 68.24 | 0.01 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 16 (showing top):
ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, ZNF577_TARGET_GENES, MIR548AJ_3P_MIR548X_3P, MIR548AE_3P_MIR548AQ_3P, MIR548AH_3P_MIR548AM_3P, MIR548J_3P, MIR139_5P, MIR7855_5P, WP_PREIMPLANTATION_EMBRYO, ZNF623_TARGET_GENES, ZNF101_TARGET_GENES, ZNF555_TARGET_GENES, GOMF_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY, PULVER_FOREY_PERTURB_ATTRITION_G1_S
GO Biological Process (1): regulation of transcription by RNA polymerase II (GO:0006357)
GO Molecular Function (2): DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700)
GO Cellular Component (1): nucleus (GO:0005634)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| regulation of DNA-templated transcription | 2 |
| transcription by RNA polymerase II | 1 |
| nucleic acid binding | 1 |
| transcription cis-regulatory region binding | 1 |
| transcription regulator activity | 1 |
| intracellular membrane-bounded organelle | 1 |
Protein interactions and networks
STRING
150 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| NANOGNB | DPRX | A6NFQ7 | 721 |
| NANOGNB | TPRX1 | Q8N7U7 | 667 |
| NANOGNB | ANHX | E9PGG2 | 645 |
| NANOGNB | ARGFX | A6NJG6 | 623 |
| NANOGNB | DUXB | A0A1W2PPF3 | 609 |
| NANOGNB | PRAMEF17 | Q5VTA0 | 604 |
| NANOGNB | LEUTX | A8MZ59 | 581 |
| NANOGNB | PRAMEF20 | Q5VT98 | 555 |
| NANOGNB | DUXA | A6NLW8 | 548 |
| NANOGNB | RHOXF2B | P0C7M4 | 480 |
| NANOGNB | CT45A3 | P0DMU6 | 418 |
| NANOGNB | AICDA | Q9GZX7 | 395 |
| NANOGNB | CT45A10 | P0DMU9 | 392 |
| NANOGNB | CT45A5 | P0DMU8 | 372 |
| NANOGNB | RHOXF2 | Q9BQY4 | 370 |
| NANOGNB | RAX2 | Q96IS3 | 370 |
IntAct
2 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| NANOGNB | PRKCSH | psi-mi:“MI:0915”(physical association) | 0.400 |
BioGRID (3): NANOGNB (Two-hybrid), NANOGNB (Proximity Label-MS), NANOGNB (Cross-Linking-MS (XL-MS))
ESM2 similar proteins: A0A1B0GVG6, A6NE01, C0H3T6, G3UW99, P0C6L1, P0CT86, P11459, P19507, P31628, P32933, P32934, P32935, P33460, P34493, P46916, P84712, Q02838, Q03328, Q08561, Q09020, Q0ZNK1, Q27976, Q2TBV0, Q3E795, Q4V7B4, Q55H65, Q5H9L2, Q5MJ07, Q5MJ08, Q5MJ09, Q5SY13, Q5T7N2, Q6IPX3, Q6SJ84, Q6SJ91, Q7Z5D8, Q86TU6, Q8IZT9, Q8IZU0, Q8LAX3
Diamond homologs: P49796, Q05481, Q7Z5D8, Q96CB5, Q9NRJ1, A0A2R8Y7D0, Q9P1C3
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
30 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 26 |
| Likely benign | 2 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
362 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 12:7770148:G:GT | donor_gain | 0.9900 |
| 12:7770149:A:T | donor_gain | 0.9900 |
| 12:7770159:G:GT | donor_gain | 0.9900 |
| 12:7770160:A:T | donor_gain | 0.9900 |
| 12:7770438:GATAA:G | acceptor_gain | 0.9900 |
| 12:7770166:G:T | donor_gain | 0.9800 |
| 12:7770166:GAAAA:G | donor_gain | 0.9800 |
| 12:7770201:A:G | donor_gain | 0.9800 |
| 12:7770514:ATGAG:A | donor_loss | 0.9800 |
| 12:7770515:TGAG:T | donor_loss | 0.9800 |
| 12:7770516:GAGGT:G | donor_loss | 0.9800 |
| 12:7770517:AG:A | donor_loss | 0.9800 |
| 12:7770518:GG:G | donor_loss | 0.9800 |
| 12:7770519:GTAAG:G | donor_loss | 0.9800 |
| 12:7770520:T:TC | donor_loss | 0.9800 |
| 12:7773796:ACAG:A | acceptor_loss | 0.9800 |
| 12:7773797:CA:C | acceptor_loss | 0.9800 |
| 12:7773798:A:AG | acceptor_gain | 0.9800 |
| 12:7773798:AGA:A | acceptor_loss | 0.9800 |
| 12:7773799:G:GG | acceptor_gain | 0.9800 |
| 12:7773794:A:AG | acceptor_gain | 0.9700 |
| 12:7773798:AGAT:A | acceptor_gain | 0.9700 |
| 12:7773799:GATG:G | acceptor_gain | 0.9700 |
| 12:7770112:G:GT | donor_gain | 0.9600 |
| 12:7770521:AA:A | donor_loss | 0.9600 |
| 12:7773795:A:G | acceptor_gain | 0.9600 |
| 12:7773799:GAT:G | acceptor_gain | 0.9600 |
| 12:7765384:CAAG:C | donor_loss | 0.9500 |
| 12:7765385:AAGGT:A | donor_loss | 0.9500 |
| 12:7765386:AGGT:A | donor_loss | 0.9500 |
AlphaMissense
1248 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 12:7770451:T:C | F150L | 0.972 |
| 12:7770453:T:A | F150L | 0.972 |
| 12:7770453:T:G | F150L | 0.972 |
| 12:7770241:T:C | F121L | 0.970 |
| 12:7770243:T:A | F121L | 0.970 |
| 12:7770243:T:G | F121L | 0.970 |
| 12:7770289:T:C | F137L | 0.942 |
| 12:7770291:T:A | F137L | 0.942 |
| 12:7770291:T:G | F137L | 0.942 |
| 12:7770448:T:A | W149R | 0.940 |
| 12:7770448:T:C | W149R | 0.940 |
| 12:7770295:T:C | F139L | 0.939 |
| 12:7770297:T:A | F139L | 0.939 |
| 12:7770297:T:G | F139L | 0.939 |
| 12:7770242:T:C | F121S | 0.915 |
| 12:7770450:G:C | W149C | 0.913 |
| 12:7770450:G:T | W149C | 0.913 |
| 12:7770452:T:C | F150S | 0.901 |
| 12:7770234:G:C | W118C | 0.895 |
| 12:7770234:G:T | W118C | 0.895 |
| 12:7770440:T:A | I146K | 0.874 |
| 12:7770465:G:C | R154S | 0.870 |
| 12:7770465:G:T | R154S | 0.870 |
| 12:7770440:T:C | I146T | 0.866 |
| 12:7770284:T:C | L135P | 0.858 |
| 12:7770303:G:A | M141I | 0.856 |
| 12:7770303:G:C | M141I | 0.856 |
| 12:7770303:G:T | M141I | 0.856 |
| 12:7770315:G:C | Q145H | 0.855 |
| 12:7770315:G:T | Q145H | 0.855 |
dbSNP variants (sampled 300 via entrez): RS1000835827 (12:7773801 T>A), RS1000971987 (12:7768059 G>A), RS1001024289 (12:7768526 T>C), RS1001194405 (12:7766074 G>C,T), RS1001289355 (12:7773999 G>C), RS1001568968 (12:7766242 G>T), RS1001717234 (12:7772698 A>G), RS1001822098 (12:7772345 T>C), RS1002177342 (12:7768817 C>A), RS1002781734 (12:7763420 C>A), RS1002840378 (12:7771322 A>C,G,T), RS1003037829 (12:7766006 A>T), RS1003244282 (12:7763686 C>G,T), RS1003282182 (12:7767810 G>A), RS1003895223 (12:7773735 T>A,C)
Disease associations
OMIM: gene MIM:620692 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
4 total (human), top 4 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| hydroxyhydroquinone | increases expression | 1 |
| benzo(e)pyrene | increases methylation | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Methapyrilene | increases methylation | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.